In February 2021, the US FDA approved Breyanzi (lisocabtagene maraleucel), a CAR T-cell therapy, as a treatment for DLBCL adult patients who have not responded to or relapsed after at least two lines of SOC.
▶️ 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐑𝐞𝐩𝐨𝐫𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧:- https://lnkd.in/dvh8svjb
#chimeric_antigen_receptor_t_cell_therapy #antigen #chimeric #receptor #immunotherapy #cancer #bloodcancer #lymphoma #healthcare #marknteladvisors